Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market sumatriptan succinate Tablets, 25 mg (base), 50 mg (base) and 100 mg (base). Total annual market sales for sumatriptan succinate Tablets were $857 million (+2.8%) (IMS - MAT: March 2005).

Sumatriptan succinate Tablets (Imitrex) Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.

"We are pleased to receive this tentative approval for sumatriptan succinate Tablets. This product represents a future opportunity for Ranbaxy and will be launched following final approval from the FDA that will further expand our growing portfolio of affordable generic product formulations," said Jim Meehan, Vice President of Sales and Marketing for RPI, USA.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of the company.